Herpes zoster
☆ Di encamên 2022-an de Stiftung Warentest ji Almanyayê, razîbûna xerîdar bi ModelDerm tenê ji şêwirmendên telemedicine drav hindik hindiktir bû.
Herpes zoster blisters li ser stû û mil
References
Şengal, ku ji nû ve aktîvkirina vîrusa varicella zosterê ku berpirsiyarê avika mirîşkan e, pêk tê, salane li dora 1 mîlyon mirov li Dewletên Yekbûyî bandor dike, bi xetereya jiyanê ya 30%. Kesên ku xwedan pergalên berevaniyê yên qels in, bi girîngî bêtir meyla pêşkeftina şengalê ne, digel ku nîşanên bi gelemperî bi nexweşî, serêş, û tayek sivik dest pê dikin, li dûv wan çend roj beriya xuyangkirina kezebê hestên çerm ên neasayî peyda dibin. Ev rijandin, bi gelemperî li deverek taybetî ya laş xuya dibe, di nav hefteyekê de heya deh rojan ji bilbilên zelal berbi birînên pelçiqandî pêşve diçe. Dermankirina bilez bi dermanên antîviral (acyclovir, valacyclovir, or famciclovir) di nav 72 demjimêran de piştî destpêkirina raşê pir girîng e. Neuralgiya postherpetîk, tevliheviyek hevpar a ku bi êşa dirêjkirî ya li devera bandorkirî ve tête diyar kirin, li ser yek ji pênc nexweşan bandor dike û hewceyê birêvebirina domdar bi dermanên wekî gabapentin, pregabalin, an hin antîdepresanan, ligel ajanên herêmî yên wekî lidocaine an capsaicin hewce dike. Vakslêdana li dijî vîrusa varicella zoster ji bo mezinên 50 salî û jortir tê pêşniyar kirin da ku xetera zosterê kêm bike.
Shingles, caused by the reactivation of the varicella zoster virus responsible for chickenpox, affects around 1 million people annually in the United States, with a lifetime risk of 30%. Those with weakened immune systems are significantly more prone to developing shingles, with symptoms typically starting with malaise, headache, and a mild fever, followed by unusual skin sensations a few days before the appearance of a rash. This rash, usually appearing in a specific area of the body, progresses from clear blisters to crusted sores over a week to ten days. Prompt treatment with antiviral medications (acyclovir, valacyclovir, or famciclovir) within 72 hours of rash onset is crucial. Postherpetic neuralgia, a common complication characterized by prolonged pain in the affected area, affects about one in five patients and requires ongoing management with medications such as gabapentin, pregabalin, or certain antidepressants, along with topical agents like lidocaine or capsaicin. Vaccination against the varicella zoster virus is recommended for adults aged 50 and above to reduce the risk of shingles.
Shingles, caused by the reactivation of the varicella zoster virus responsible for chickenpox, affects around 1 million people annually in the United States, with a lifetime risk of 30%. Those with weakened immune systems are significantly more prone to developing shingles, with symptoms typically starting with malaise, headache, and a mild fever, followed by unusual skin sensations a few days before the appearance of a rash. This rash, usually appearing in a specific area of the body, progresses from clear blisters to crusted sores over a week to ten days. Prompt treatment with antiviral medications (acyclovir, valacyclovir, or famciclovir) within 72 hours of rash onset is crucial. Postherpetic neuralgia, a common complication characterized by prolonged pain in the affected area, affects about one in five patients and requires ongoing management with medications such as gabapentin, pregabalin, or certain antidepressants, along with topical agents like lidocaine or capsaicin. Vaccination against the varicella zoster virus is recommended for adults aged 50 and above to reduce the risk of shingles.
Herpes zoster di mirovên 50 salî û mezintir de, yên ku pergalên xweparastinê qels in, û yên ku dermanên immunosuppressant digirin de pir caran çêdibe. Ew bi ji nû ve aktîvkirina vîrusa varicella-zoster, heman vîrusê ku dibe sedema mirina mirîşkan, çêdibe. Nîşaneyên mîna tayê, êş û xurînê bi gelemperî pêşî li xuyangkirina tîrêjê ya taybetmendiyê digirin. Tevliheviya herî berbelav neuralgiya post-herpetîk e, ku êşa domdar a nervê ye piştî ku rash paqij dibe. Faktorên xetereyê û tevliheviyên ku bi herpes zoster re têkildar in li gorî temen, tenduristiya berevaniyê, û dema destpêkirina dermankirinê diguhere. Derzîlêdana ji bo kesên 60 salî û jortir hate destnîşan kirin ku bi girîngî rûdana herpes zoster û neuralgiya post-herpetic kêm dike. Destpêkirina dermanên antîviral û dermanên êşê di nav 72 demjimêran de piştî destpêkirina raşê dikare giranî û tevliheviyên herpes zoster û neuralgiya post-herpetîk kêm bike.
Herpes zoster tends to occur more frequently in people aged 50 and older, those with weakened immune systems, and those taking immunosuppressant medications. It's triggered by the reactivation of the varicella-zoster virus, the same virus that causes chickenpox. Symptoms like fever, pain, and itching commonly precede the appearance of the characteristic rash. The most common complication is post-herpetic neuralgia, which is persistent nerve pain after the rash clears up. The risk factors and complications associated with herpes zoster vary depending on age, immune health, and timing of treatment initiation. Vaccination for individuals aged 60 and above has been shown to significantly reduce the occurrence of herpes zoster and post-herpetic neuralgia. Starting antiviral medications and pain relievers within 72 hours of rash onset can lessen the severity and complications of herpes zoster and post-herpetic neuralgia.
Herpes zoster tends to occur more frequently in people aged 50 and older, those with weakened immune systems, and those taking immunosuppressant medications. It's triggered by the reactivation of the varicella-zoster virus, the same virus that causes chickenpox. Symptoms like fever, pain, and itching commonly precede the appearance of the characteristic rash. The most common complication is post-herpetic neuralgia, which is persistent nerve pain after the rash clears up. The risk factors and complications associated with herpes zoster vary depending on age, immune health, and timing of treatment initiation. Vaccination for individuals aged 60 and above has been shown to significantly reduce the occurrence of herpes zoster and post-herpetic neuralgia. Starting antiviral medications and pain relievers within 72 hours of rash onset can lessen the severity and complications of herpes zoster and post-herpetic neuralgia.
Lêkolînên klînîkî yên berî pejirandinê destnîşan dikin ku vakslêdana zostera zindî li dora 50 û 70% dixebite, dema ku vakslêdana rekombinant çêtir dike, ji 90 heta 97%. Di lêkolînên cîhana rastîn de, ew piştgirî didin encamên ceribandinan, û destnîşan dikin ku vakslêdana zindî bi qasî 46% bi bandor e, dema ku ya rekombînant li dora 85%.
The pre-licensure clinical trials show the efficacy of the live zoster vaccine to be between 50 and 70% and for the recombinant vaccine to be higher at 90 to 97%. Real-world effectiveness studies, with a follow-up of approximately 10 years, were reviewed in this article. These data corroborated the efficacy studies, with vaccine effectiveness being 46% and 85% for the live and recombinant vaccines, respectively.
The pre-licensure clinical trials show the efficacy of the live zoster vaccine to be between 50 and 70% and for the recombinant vaccine to be higher at 90 to 97%. Real-world effectiveness studies, with a follow-up of approximately 10 years, were reviewed in this article. These data corroborated the efficacy studies, with vaccine effectiveness being 46% and 85% for the live and recombinant vaccines, respectively.
Kulika mirîşkê, ku jê re varicella jî tê gotin, ji enfeksiyona destpêkê ya bi vîrusê re, bi gelemperî di zaroktî an xortaniyê de çêdibe. Piştî ku zozana mirîşkê qenc bû, vîrus dikare bi salan an bi deh salan di nav şaneyên nervê yên mirovan de neçalak (xewî) bimîne, piştî ku dibe ku ji nû ve çalak bibe. Herpes zoster dema ku vîrusa varicella ya razayî ji nû ve tê aktîfkirin encam dide. Dûv re vîrus bi laşên nervê re digihêje dawiya nervê ya di çerm de, bilbilan çêdike. Di dema derketina herpes zoster de, rûbirûbûna vîrusa varicella ya ku di blisterên herpes zoster de tê dîtin, dikare di kesê ku hîna neketibe mirîşkê bibe sedema mirina mirîşkan.
Faktorên metirsiyê yên ji nû ve aktîvkirina vîrusa razanê, kalbûn, fonksiyona belengaziya belengaz, û berî 18 mehî bi nexweşiya mirîşkê ketine. Vîrûsa Varicella zoster ne wekî virusê herpes simplex e, her çend her du jî ji heman malbata herpesviruses in.
Derziyên herpes zoster rîska herpes zoster ji %50 heta 90% kêm dike. Di heman demê de ew rêjeyên neuralgiya postherpetîk jî kêm dike, û heke herpes zoster çêbibe, giraniya wê jî kêm dike. Ger herpes zoster pêşve bibe, dermanên antîviral ên wekî aciclovir dikarin giranî û dirêjahiya nexweşiyê kêm bikin heke di nav 72 demjimêran de piştî xuyabûna raşê dest pê bikin.
○ Demankirinî
Ger birîn bi lez belav dibin, ji bo dermankirina antîvîrusê ji bo dermankirina antîvîrus di zûtirîn dem de doktorê xwe bibînin.
Hem dermanên antiviral û hem jî dermanên neuralgiyê hewce ne. Divê hûn bêhna xwe bidin û dev ji vexwarina alkolê berdin.
#Acyclovir
#Fancyclovir
#Valacyclovir
#Gabapentin
#Pregabalin